Won-Keun Kim1, Andreas Rolf2, Christoph Liebetrau3, Arnaud Van Linden3, Johannes Blumenstein3, Jörg Kempfert4, Georg Bachmann5, Holger Nef6, Christian Hamm2, Thomas Walther4, Helge Möllmann7. 1. Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany; Department of Cardiac Surgery, Kerckhoff Heart Center, Bad Nauheim, Germany. 2. Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany; Department of Cardiology, University of Giessen, Giessen, Germany. 3. Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany. 4. Department of Cardiac Surgery, Kerckhoff Heart Center, Bad Nauheim, Germany. 5. Department of Radiology, Kerckhoff Heart Center, Bad Nauheim, Germany. 6. Department of Cardiology, University of Giessen, Giessen, Germany. 7. Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany. Electronic address: h.moellmann@kerckhoff-klinik.de.
Abstract
BACKGROUND: Myocardial injury after transcatheter aortic valve replacement (TAVR) is common, but its cause and relationship to the extent of myocardial tissue loss remain unclear. OBJECTIVES: This study sought to examine the incidence and degree of ischemic myocardial damage using cardiac magnetic resonance imaging and myocardial biomarkers in patients undergoing TAVR. METHODS: Patients with severe aortic stenosis (n = 61) underwent cardiac magnetic resonance imaging before and after TAVR for the assessment of new myocardial injury. High-sensitivity cardiac troponin T and creatine kinase-myocardial band were measured before and at 24, 48, and 72 h after TAVR. RESULTS: After TAVR, new myocardial late enhancement (LE) with an ischemic pattern occurred in 11 patients (18%), with a mean mass of 3.7 g (interquartile range: 1.2 to 6 g) or 1.8% (interquartile range: 1.3% to 4.1%) of the left ventricular mass. Patients with new LE had a decreased left ventricular function (ejection fraction: pre, 55.5 ± 14.1% vs. post, 45.3 ± 14.9%; p = 0.001). In patients without new LE, no differences were observed (ejection fraction: pre, 53.9 ± 17.3% vs. post, 54.6 ± 16.3%; p = NS) after TAVR. CONCLUSIONS: New ischemic-type myocardial LE after TAVR can be observed in a notable proportion of patients and is assumed to be of embolic origin. Patients with new LE feature a significant decrease in left ventricular function at discharge.
BACKGROUND:Myocardial injury after transcatheter aortic valve replacement (TAVR) is common, but its cause and relationship to the extent of myocardial tissue loss remain unclear. OBJECTIVES: This study sought to examine the incidence and degree of ischemic myocardial damage using cardiac magnetic resonance imaging and myocardial biomarkers in patients undergoing TAVR. METHODS:Patients with severe aortic stenosis (n = 61) underwent cardiac magnetic resonance imaging before and after TAVR for the assessment of new myocardial injury. High-sensitivity cardiac troponin T and creatine kinase-myocardial band were measured before and at 24, 48, and 72 h after TAVR. RESULTS: After TAVR, new myocardial late enhancement (LE) with an ischemic pattern occurred in 11 patients (18%), with a mean mass of 3.7 g (interquartile range: 1.2 to 6 g) or 1.8% (interquartile range: 1.3% to 4.1%) of the left ventricular mass. Patients with new LE had a decreased left ventricular function (ejection fraction: pre, 55.5 ± 14.1% vs. post, 45.3 ± 14.9%; p = 0.001). In patients without new LE, no differences were observed (ejection fraction: pre, 53.9 ± 17.3% vs. post, 54.6 ± 16.3%; p = NS) after TAVR. CONCLUSIONS: New ischemic-type myocardial LE after TAVR can be observed in a notable proportion of patients and is assumed to be of embolic origin. Patients with new LE feature a significant decrease in left ventricular function at discharge.
Authors: Won-Keun Kim; Christoph Liebetrau; Arnaud van Linden; Johannes Blumenstein; Luise Gaede; Christian W Hamm; Thomas Walther; Helge Möllmann Journal: Clin Res Cardiol Date: 2015-12-15 Impact factor: 5.460
Authors: Luise Gaede; Won-Keun Kim; Christoph Liebetrau; Oliver Dörr; Johannes Sperzel; Johannes Blumenstein; Alexander Berkowitsch; Thomas Walther; Christian Hamm; Albrecht Elsässer; Holger Nef; Helge Möllmann Journal: Clin Res Cardiol Date: 2017-09-29 Impact factor: 5.460
Authors: Konstantinos C Koskinas; Stefan Stortecky; Anna Franzone; Crochan J O'Sullivan; Fabien Praz; Katazyrna Zuk; Lorenz Räber; Thomas Pilgrim; Aris Moschovitis; Georg M Fiedler; Peter Jüni; Dik Heg; Peter Wenaweser; Stephan Windecker Journal: J Am Heart Assoc Date: 2016-02-19 Impact factor: 5.501
Authors: Luise Gaede; Johannes Blumenstein; Christoph Liebetrau; Oliver Dörr; Won-Keun Kim; Holger Nef; Oliver Husser; Albrecht Elsässer; Christian W Hamm; Helge Möllmann Journal: Eur Heart J Date: 2018-02-21 Impact factor: 29.983
Authors: Matthias Schindler; Florin Stöckli; Rico Brütsch; Philipp Jakob; Erik Holy; Jonathan Michel; Robert Manka; Paul Vogt; Christian Templin; Markus Kasel; Frank Ruschitzka; Barbara E Stähli Journal: J Am Heart Assoc Date: 2021-10-29 Impact factor: 5.501
Authors: Jennifer Mancio; Ricardo Fontes-Carvalho; Marco Oliveira; Daniel Caeiro; Pedro Braga; Nuno Bettencourt; Vasco Gama Ribeiro Journal: Front Cardiovasc Med Date: 2015-04-15
Authors: Tarique A Musa; Thomas A Treibel; Vassiliou S Vassiliou; Gabriella Captur; Anvesha Singh; Calvin Chin; Laura E Dobson; Silvia Pica; Margaret Loudon; Tamir Malley; Marzia Rigolli; James R J Foley; Petra Bijsterveld; Graham R Law; Marc R Dweck; Saul G Myerson; Gerry P McCann; Sanjay K Prasad; James C Moon; John P Greenwood Journal: Circulation Date: 2018-10-30 Impact factor: 29.690